iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $100.38, for a total transaction of $501,900.00. Following the transaction, the chief executive officer owned 2,235,000 shares in the company, valued at $224,349,300. The trade was a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

iRadimed Stock Performance

iRadimed stock traded up $0.81 during trading on Wednesday, reaching $101.78. 52,623 shares of the company’s stock were exchanged, compared to its average volume of 74,394. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $107.90. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of 58.16 and a beta of 1.12. The company’s 50-day moving average is $100.53 and its two-hundred day moving average is $90.14.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. The company had revenue of $22.69 million for the quarter, compared to analyst estimates of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a dividend of $0.20 per share. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed’s dividend payout ratio is presently 45.71%.

Analysts Set New Price Targets

Several analysts have issued reports on IRMD shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $120.00.

Institutional Investors Weigh In On iRadimed

A number of hedge funds have recently bought and sold shares of IRMD. CWM LLC increased its holdings in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP acquired a new stake in iRadimed in the third quarter valued at $40,000. Farther Finance Advisors LLC boosted its stake in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in iRadimed during the 3rd quarter worth $47,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.